Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Claudia Djambas Khayat, Genadi Iosava, Irina Romashevskaya, Oleksandra Stasyshyn, Marta Julia Lopez, Maria Teresa Pompa, Tobias Rogosch & Wilfried Seifert. (2021) Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study). Journal of Blood Medicine 12, pages 483-495.
Read now
Read now
Dorothy M Adcock, Mazi Rasulnia, Natalia Holot & David L Cooper. (2018) Educational needs of hematologists and laboratory professionals regarding factor activity assays. Journal of Blood Medicine 9, pages 51-59.
Read now
Read now
Alessandro Gringeri, Katharina Steinitz-Trost & Jennifer Doralt. (2017) Current and future approaches to overcoming the challenges of hemophilia treatment personalization. Expert Opinion on Orphan Drugs 5:7, pages 589-597.
Read now
Read now
Olubunmi Afonja, Robert Kozak, Paul Petraro, Lisa A. Michaels, Prasad Mathew, Georg Lemm & Craig Kessler. (2016) Baby hamster kidney cell–derived recombinant factor VIII: a quarter century of learning and clinical experience. Expert Review of Hematology 9:12, pages 1151-1164.
Read now
Read now
Alessandro Gringeri, Jennifer Doralt, Leonard A. Valentino, Roberto Crea & Armin J. Reininger. (2016) An innovative outcome-based care and procurement model of hemophilia management. Expert Review of Pharmacoeconomics & Outcomes Research 16:3, pages 337-345.
Read now
Read now
Lindsey A George & Rodney M Camire. (2015) Profile of efraloctocog alfa and its potential in the treatment of hemophilia A. Journal of Blood Medicine 6, pages 131-141.
Read now
Read now
Articles from other publishers (39)
Tine M.H.J. Goedhart, A. Janssen, Ron A.A. Mathôt & Marjon H. Cnossen. (2023) The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators. Blood Reviews 61, pages 101098.
Crossref
Crossref
Limin Wang, Shimeng Liu, Shan Jiang, Chaofan Li, Liyong Lu, Yunhai Fang & Shunping Li. (2023) Quantifying Benefit-Risk Trade-Offs Toward Prophylactic Treatment Among Adult Patients With Hemophilia A in China: Discrete Choice Experiment Study. JMIR Public Health and Surveillance 9, pages e45747.
Crossref
Crossref
Isaiah A. Reeves, Rebecca S. Blue, Serena Auñon-Chancellor, Michael F. Harrison, Ronak Shah & William E. Powers. (2023) Tolerance of Centrifuge-Simulated Commercial Spaceflight in a Subject with Hemophilia A. Aerospace Medicine and Human Performance 94:6, pages 470-474.
Crossref
Crossref
Michael A. Nardi. 2023.
273
315
.
Margareth Castro Ozelo, Sandra Vallin Antunes, Paula Ribeiro Villaca, Luciana Correa Oliveira, Ieda Solange Pinto, Claúdia Santos Lorenzato, Alessandra Nunes Loureiro Prezotti & Renato Mantelli Picoli. (2022) Extended half-life recombinant factor VIII treatment of hemophilia A in Brazil: an expert consensus statement. Hematology, Transfusion and Cell Therapy.
Crossref
Crossref
Jamil Hmida, Thomas Hilberg, Pia Ransmann, Fabian Tomschi, Claudia Klein, Sebastian Koob, Alexander Franz, Heinrich Richter, Johannes Oldenburg & Andreas C. Strauss. (2022) Most subjectively affected joints in patients with haemophilia – what has changed after 20 years in Germany?. Haemophilia 28:4, pages 663-670.
Crossref
Crossref
Michael Recht, Chunla He, Er. Chen, Dunlei Cheng, Paul Solari & David Hinds. (2022) Resource utilization and treatment costs of patients with severe hemophilia A: Real‐world data from the ATHNdataset. eJHaem 3:2, pages 341-352.
Crossref
Crossref
Paolo Angelo Cortesi, Angiola Rocino, Daniele Preti, Anna Fragomeno, Francesco Cucuzza, Nicola Ceresi, Cristina Santoro, Antonietta Ferretti, Arianna Fornari, Ippazio Cosimo Antonazzo, Rita Facchetti, Paolo Cozzolino, Chiara Biasoli, Cristina Cassone, Antonio Coppola & Lorenzo G. Mantovani. (2022) Haemophilia management and treatment: An Italian survey on patients’, caregivers’ and clinicians’ point of view. Haemophilia 28:2, pages 254-263.
Crossref
Crossref
Emine Türkkan, Gül Nihal Özdemir, Öykü Arslan, Serap Karaman, Zeynep Karakaş & Ayşegül Ünüvar. (2022) Improved clinical outcome after PK-Guided Personalised Prophylaxis with my-PKFIT® in patients with hemophilia A without inhibitors. Medical Science and Discovery 9:2.
Crossref
Crossref
Youqun Wang, Qiao Yang, Liangda Zheng, Xianting Wang, Wenhua Jiang, Lijun Lu, Lixia Yan, Miaomiao Zhang & Lili Chen. (2022) Efficacy of Individualized Preventive Treatment of Patients with Severe Hemophilia A Guided by Multiple Clinical Parameters and Pharmacokinetics. Acta Haematologica 145:4, pages 354-361.
Crossref
Crossref
Craig D. Seaman, Frederico Xavier & Margaret V. Ragni. (2021) Hemophilia A (Factor VIII Deficiency). Hematology/Oncology Clinics of North America 35:6, pages 1117-1129.
Crossref
Crossref
Paolo Angelo Cortesi, Adele Giampaolo, Francesca Abbonizio, Angelo Claudio Molinari, Giancarlo Castaman, Mauro Biffoni & Lorenzo Giovanni Mantovani. (2021) Variability of treatment modalities and intensity in patients with severe haemophilia A on prophylaxis: Results from the Italian national registry. European Journal of Haematology 107:4, pages 408-415.
Crossref
Crossref
Juan Eduardo Megías-Vericat, Santiago Bonanad, Saturnino Haya, Ana Rosa Cid, María Remedios Marqués, Alejandra Ferrada, Emilio Monte-Boquet, Sofía Pérez-Alenda, Pau Bosch, Felipe Querol-Giner & Jose Luis Poveda. (2021) Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients. Thrombosis Research 205, pages 99-105.
Crossref
Crossref
Maria Elisa Mancuso, Mark T. Reding, Claude Negrier, Bryce A. Kerlin, Savita Rangarajan & Mindy L. Simpson. (2020) Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thrombosis and Haemostasis 121:08, pages 1079-1086.
Crossref
Crossref
Victoire Pitance, Stéphanie Désage, Anne Lienhart, Sandrine Meunier & Valérie Chamouard. (2021) Haemophilia A patients' medication adherence to prophylaxis with efmoroctocog alfa. Haemophilia 27:3.
Crossref
Crossref
Robert Klamroth, Jerzy Windyga, Vlad Radulescu, Peter W. Collins, Oleksandra Stasyshyn, Hishamshah Mohd Ibrahim, Werner Engl, Srilatha D. Tangada, William Savage & Bruce Ewenstein. (2021) Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood 137:13, pages 1818-1827.
Crossref
Crossref
Armando Tripodi, Veena Chantarangkul, Cristina Novembrino, Erica Scalambrino, Massimo Boscolo-Anzoletti, Marigrazia Clerici, Federica Rossi & Flora Peyvandi. (2021) Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma. Clinical Chemistry and Laboratory Medicine (CCLM) 59:2, pages 365-371.
Crossref
Crossref
Tekin AKSU, Vildan KOŞAN, Zühre KAYA, Zeliha GUZELKUCUK, Dilek GÜRLEK GÖKÇEBAY, Hüsniye Neşe YARALI & Namık Yaşar ÖZBEK. (2020) Kalıtsal Faktör VIII Eksikliği Hastalarında Rekombinan FVIII’in Farmakokinetik Verileri. Turkish Journal of Pediatric Disease, pages 1-5.
Crossref
Crossref
Zheng-Yi ZhouKarina RaimundoAnisha M. PatelSimeng HanYusi JiHonghao FangJia ZhongKeith A. BettsArash Mahajerin. (2020) Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A. Journal of Managed Care & Specialty Pharmacy 26:9, pages 1109-1120.
Crossref
Crossref
Beatrice Nolan, Johnny Mahlangu, Ingrid Pabinger, Guy Young, Barbara A. Konkle, Chris Barnes, Keiji Nogami, Elena Santagostino, K. John Pasi, Liane Khoo, Bent Winding, Huixing Yuan, Joachim Fruebis, Dan Rudin & Johannes Oldenburg. (2020) Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia 26:3, pages 494-502.
Crossref
Crossref
Pierre Chelle, Cindy H. T. Yeung, Stacy E. Croteau, Jennifer Lissick, Vinod Balasa, Christina Ashburner, Young Shil Park, Santiago Bonanad, Juan Eduardo Megías-Vericat, Azusa Nagao, Tung Wynn, Fernando Corrales-Medina, Huyen Tran, Anjali Sharathkumar, Meera Chitlur, Samuel Sarmiento, Andrea Edginton & Alfonso Iorio. (2019) Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. Clinical Pharmacokinetics 59:2, pages 245-256.
Crossref
Crossref
Thomas Hughes, Mikkel Brok-Kristensen, Yosha Gargeya, Anne Mette Worsøe Lottrup, Ask Bo Larsen, Ana Torres-Ortuño, Nicki Mackett & John Stevens. (2020) Treating for stability: an ethnographic study of aspirations and limitations in haemophilia treatment in Europe. The Journal of Haemophilia Practice 7:1, pages 165-172.
Crossref
Crossref
Jane R. Wells, Adam Gater, Chris Marshall, Theo Tritton, Parth Vashi & Sophia Kessabi. (2019) Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII). The Patient - Patient-Centered Outcomes Research 12:6, pages 611-619.
Crossref
Crossref
Shadan Lalezari, Mark T. Reding, Ingrid Pabinger, Pal Andre Holme, Claude Negrier, Pavani Chalasani, Ho‐Jin Shin, Maria Wang, Despina Tseneklidou‐Stoeter & Monika Maas Enriquez. (2019) BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. Haemophilia 25:6, pages 1011-1019.
Crossref
Crossref
Charles Nakar & Amy Shapiro. (2019) Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time. Transfusion and Apheresis Science 58:5, pages 578-589.
Crossref
Crossref
Pierre Chelle, Cindy H. T. Yeung, Santiago Bonanad, Juan Cristóbal Morales Muñoz, Margareth C. Ozelo, Juan Eduardo Megías Vericat, Alfonso Iorio, Jeffrey Spears, Roser Mir & Andrea Edginton. (2019) Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. Journal of Pharmacokinetics and Pharmacodynamics 46:5, pages 427-438.
Crossref
Crossref
Julia Paik & Emma D. Deeks. (2019) Damoctocog Alfa Pegol: A Review in Haemophilia A. Drugs 79:10, pages 1147-1156.
Crossref
Crossref
Xavier Delavenne, Yesim Dargaud, Edouard Ollier & Claude Négrier. (2019) Dose tailoring of human cell line‐derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A. British Journal of Clinical Pharmacology 85:4, pages 771-781.
Crossref
Crossref
J.E. Megías-Vericat, S. Bonanad, S. Haya, A.R. Cid, M.R. Marqués, E. Monte, S. Pérez-Alenda, P. Bosch, F. Querol & J.L. Poveda. (2019) Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A. Thrombosis Research 174, pages 151-162.
Crossref
Crossref
E. Carlos Rodriguez-Merchan & Leonard A. Valentino. (2019) Emicizumab: Review of the literature and critical appraisal. Haemophilia 25:1, pages 11-20.
Crossref
Crossref
Gitte Lee Mortensen, Anne Mette Strand & Lisa Almén. (2018) Adherence to prophylactic haemophilic treatment in young patients transitioning to adult care: A qualitative review. Haemophilia 24:6, pages 862-872.
Crossref
Crossref
M. E. Mingot-Castellano, R. Parra, R. Núñez & M. Martorell. (2018)
Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT
®
. Haemophilia 24:5, pages e338-e343.
Crossref
Crossref
C. Hermans, J. Mahlangu, J. Booth, H. Schütz, E. Santagostino, G. Young, H.-Y. Lee, K. N. Steinitz-Trost, V. Blanchette & E. Berntorp. (2018) Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. Haemophilia 24:3, pages 376-384.
Crossref
Crossref
E. Berntorp, A. Ågren, L. Aledort, M. Blombäck, M. H. Cnossen, S. E. Croteau, M. von Depka, A. B. Federici, A. Goodeve, J. Goudemand, P. M. Mannucci, M. Mourik, P. T. Önundarson, F. Rodeghiero, T. Szántó & J. Windyga. (2018) Fifth Åland Island conference on von Willebrand disease. Haemophilia 24, pages 5-19.
Crossref
Crossref
X. Cheng, P. Li, Z. Chen, N. Zhang, Y. Zhen, L. Zhao, X. Wang & R. Wu. (2017)
Break‐through bleeding in relation to pharmacokinetics of Factor
VIII
in paediatric patients with severe haemophilia A
. Haemophilia 24:1, pages 120-125.
Crossref
Crossref
Haowei Linda Sun, Kam A. McIntosh, Sandra J. Squire, Ming Yang, Claude Bartholomew, Deb S. Gue, Pat G. Camp & Shannon C. Jackson. (2017) Patient powered prophylaxis: A 12-month study of individualized prophylaxis in adults with severe haemophilia A. Haemophilia 23:6, pages 877-883.
Crossref
Crossref
M.T. Reding, H.J. Ng, L.H. Poulsen, M.E. Eyster, I. Pabinger, H.J. Shin, R. Walsch, M. Lederman, M. Wang, M. Hardtke & L.A. Michaels. (2017) Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII. Journal of Thrombosis and Haemostasis 15:3, pages 411-419.
Crossref
Crossref
M. T. Álvarez‐Román, I. Fernandez‐Bello, H. de la Corte‐Rodríguez, A. L. Hernández‐Moreno, M. Martín‐Salces, N. Butta‐Coll, M. I. Rivas‐Pollmar, S. Rivas‐Muñoz & V. Jiménez‐Yuste. (2017)
Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT
®
in patients with severe haemophilia A without inhibitors
. Haemophilia 23:1.
Crossref
Crossref
Erik Berntorp, Yesim Dargaud, Daniel Hart, Sébastien Lobet, Maria Elisa Mancuso, Roseline d'Oiron, David Perry, Debra Pollard, Marijke van den Berg, Jan Blatný, Hervé Chambost, Andrea S. Doria, Pål André Holme, Radoslaw Kaczmarek, Lorenzo Mantovani, Paul McLaughlin, Lochana Nanayakkara, Pia Petrini, Thomas Sannié, Edward Laane, Raquel Maia, Athina Dettoraki, Anna Farrell, Susan Halimeh, Sayma Raza & Stephanie Taylor. (2017) The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany. European Journal of Haematology 98, pages 1-15.
Crossref
Crossref